We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.225 | 197,551 | 07:33:52 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.20 | 1.25 | 1.225 | 1.225 | 1.225 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | USD 891k | USD -11.89M | USD -0.0098 | -1.24 | 14.79M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:59:07 | O | 16,072 | 1.2444 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/3/2025 | 20:34 | ALNC |  IN BRIEF: Polarean Imaging expands Xenon MRI imaging platform |
| 10/3/2025 | 07:00 | UK RNS | Polarean Imaging PLC Expansion of Xenon MRI imaging platform |
| 27/2/2025 | 07:00 | UK RNS | Polarean Imaging PLC FY24 trading update |
| 19/2/2025 | 07:00 | UK RNS | Polarean Imaging PLC Virtual Investor Day |
| 03/2/2025 | 14:23 | ALNC | Polarean Imaging shares jump as inks first distribution deal in Taiwan |
| 03/2/2025 | 07:00 | UK RNS | Polarean Imaging PLC Taiwanese distributor agreement with Sumtage |
| 31/1/2025 | 16:36 | ALNC | EARNINGS AND TRADING: Tullow eyes non-core sales; Treatt backs outlook |
| 30/1/2025 | 07:00 | UK RNS | Polarean Imaging PLC Key patent in China secured |
| 28/1/2025 | 07:00 | UK RNS | Polarean Imaging PLC Collaboration to Advance Lung Imaging Innovation |
| 24/1/2025 | 07:00 | UK RNS | Polarean Imaging PLC Block Listing Six Monthly Return |
Polarean Imaging (POLX) Share Charts1 Year Polarean Imaging Chart |
|
1 Month Polarean Imaging Chart |
Intraday Polarean Imaging Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/3/2025 | 10:45 | Polarean Imaging PLC | 8,534 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:59:08 | 1.24 | 16,072 | 200.00 | O |
| 15:44:31 | 1.24 | 4,525 | 56.31 | O |
| 14:38:36 | 1.23 | 10,200 | 125.21 | O |
| 11:31:23 | 1.25 | 40,096 | 500.00 | O |
| 10:26:28 | 1.25 | 18,043 | 225.00 | O |
| Top Posts |
|---|
Posted at 30/1/2025 19:24 by goldbutler This ,current,CEO Dr Von Jacko and Board of Directors all highly paid in cash, bonuses and options has the sheer effrontery to use words in relation to the China patent such as" in our mission to optimise lung health globally.....when the time is right,". 3 years after applying for FDA approval and almost 6 million in cash and options for Von Jacko and the Board of Directors .. together with a fund raise which lasted almost 18 months - which he "discussed" with Bracco and Nukem and allowed them to take almost 35% of the company. When you consider the price and amounts subscribed for by Amati and other UK fund managers - in earlier funding together with Brokers sales and revenue figures - it is not difficult to see the utter failure to move the share price. When is "when the time is right,." for this CEO to address shareholders and update the market on the first de novo sale - previously announced or the results for year to December 2024 or the Application to FDA -forecast to be in the last quarter of 2024 or the long covid study in the UK There are those on the other board claiming that commercial traction isn't all about Sales and Revenue - Have a look at the share price and share price graph and director share buying versus directors fees and salaries and options. And the 1.2 billion shares in issue. Shareholders on AIM are the last thing on this CEO von Jacko's mind this is all about him - and his directors and Bracco and Nukem |
Posted at 21/12/2024 13:43 by goldbutler The Chairman Ken West is delivering nothing - he is a failure.his latest income is around $75,000 not counting options granted The Ceo dr von jacko is delivering nothing and he is a failure and his half year pay was around $440,000 not counting options granted. he is on just short of a million a year in cash. On 13 feb 2023 Polarean had 16 million in cash and stated The Company anticipates converting 9 research sites to FDA approved configuration and clinical use, selling 75 to 100 Xenoview Gas Blend cylinders and 15 to 20 Polarizer systems over the next 24 months. In their own words 15-20 - which is way short of their brokers forecast when they raised funds of around 27million This Von jacko and West along with Bracco and Nukem are untrustworthy They have squandered Cash on themselves - with no sign of any cutbacks on their salaries They have now 28 employees They have failed to deliver They have diluted shareholders with 1 billion shares issue they have crashed the market cap and share price They haven't sold 15 or 20 machines in 24 months They are a complete failure and their refusal to partner into the UK or other countries is unbelievable WEst the chairman is a failure and has sucked every cent he can from the company and Aim asset managers and institutional investors are now shunning the share Von Jacko was a failure at brainsway in Tel Aviv he is a complete failure and it is a measure of the individual that he can boast about an oversubscribed fund raise - but sink the share price from 28p to 1p per share |
Posted at 17/12/2024 14:43 by goldbutler West and the Board of Directors are untrustworthy. The share price graph tells the storyThey cannot even use the word shareholders - it is all stakeholders and employees and then investors bracco and nukem The share price graph tells the story - and the share register- of major shareholders - all soured by the behaviour of the broker and the USA directors. |
Posted at 29/11/2024 08:50 by moontheloon In case anyone missed this, not as much as the directors missed their targets... tell you what let's just re price our gift options for doing Jack and so we will only have to achieve Jack to receive our freebies !!!....Repricing of Options and Grant of Options Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, announces that upon the recommendation of the Company's Remuneration Committee, it has repriced existing options over ordinary shares of £0.00037 each in the capital of the Company ("Ordinary Shares") ("Share Options") over an aggregate of 19,849,965 Ordinary Shares and granted Share Options over an aggregate 121,022,451 Ordinary Shares to certain Directors, employees, and consultants of the Company. The Company's Remuneration Committee recognises the importance of share options to appropriately incentivise and retain Directors and employees as well as to ensure their interests are aligned with that of Company and its shareholders. Following a review of incentive plans, the Remuneration Committee of the Board recommended that, given the reduction in the Company's share price and the changes in the share capital following the recent fundraising, the existing awards of share options were no longer a reasonable incentive and should be amended to re-align the option scheme with the current share price and share capital. The Company contracted with a third-party compensation firm to perform a benchmarking analysis of Share Options at comparable companies. The Remuneration Committee and Board used the third-party report in determining the number of new Share Options to be issued.The repricing and granting of Share Options is pursuant to the terms of the Company's existing Stock Option Plan. 25% of the new Share Options will vest on 26 July 2025 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2025. The Share Options will be exercisable at a price of 1.83p each per Ordinary Share, being the share price as at close of business on Friday 26 July 2024. The repriced Share Options retain their original vesting and expiration terms. 17,462,194 Share Options have been repriced and 104,810,222 Share Options were granted to the 11 PDMRs listed in the table below. 2,387,771 Share Options have been repriced and 16,212,229 new Share Options were granted, to non-PDMR employees and a consultant. NameShare Options RepricedShare Options GrantedTotal no. of options over ordinary shares now heldChristopher von Jako 5,325,000 24,368,006 29,693,006Bastiaan Driehuys 1,686,000 20,040,590 21,726,590Kenneth West 2,263,218 15,842,273 18,105,491Charles Osborne 1,700,000 7,956,262 9,656,262Cyrille Petit 500,000 4,448,834 4,948,834Juergen Laucht 884,400 4,064,434 4,948,834Frank Schulkes 500,000 2,879,691 3,379,691Daniel Brague 500,000 2,879,691 3,379,691Alexander Dusek 1,500,000 8,156,262 9,656,262Neil Wadehra 1,568,988 7,242,351 8,811,339Kiarash Emami 1,034,588 6,931,828 7,966,416Total17,462 |
Posted at 25/11/2024 09:30 by m_night10 The 200DMA will soon be at low 2p level by the end of this week.Once it's there the technical lot are going to pile in as the price sits above the 50DMA and 100DMA. Then once it clears the 200DMA it goes to fill the gap to 3.4p They are already showing up to get their large amount of followers in. Recent interviews, news and articles has put this on radards. What will get it there? The following facts and news which is starting to come in. Mcap is tiny and cash position is huge to Q2 2026 and revenues are soaring.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, no |
Posted at 21/11/2024 11:26 by m_night10 The 200DMA is going to be down to the low 2p level in about a week.Once it's there the technical lot are going to pile in as the price sits above the 50DMA and 100DMA. Then once it clears the 200DMA it goes to fill the gap to 3.4p They are already showing up to get their large amount of followers in. Case in point: 1. Stocksaimtrader/stat 2. Darrenukdaytra1/stat 3. ZaksTradersCafe/stat What will get it there? The following facts and news which is starting to come in. Mcap is tiny and cash position is huge to Q2 2026 and revenues are soaring.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, no |
Posted at 15/11/2024 10:20 by m_night10 You waste your time and life moon. A few buys like the 740k you see now and it will go to 2p and then over with news faster than you can blink. :)POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations. Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 14/11/2024 09:11 by m_night10 POLX Polarean Imaging about to break out well above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.6p and gap at to 3.4p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 08:36 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap only $25mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 17/10/2024 15:19 by m_night10 POLX Mcap sub $20MIL right now I see it as a steal for Xenon MRI. No company debt, masssive growth potential, important best in class next generation MRI.1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
